Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

摘要: Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for treatment chronic myeloid leukemia. This review bosutinib summarizes mode action, pharmacokinetics, efficacy and safety data, as well patient-focused perspective through quality-of-life data. has shown considerable sustained leukemia, especially phase, with resistance or intolerance to prior inhibitors. distinct but manageable adverse events. In absence T315I V299L mutations, there are no absolute contraindications use this patient population.